Flagship Harbor Advisors LLC purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) ...

Fifth Third Bancorp cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by ...

BofA lowered the firm’s price target on Charles River (CRL) to $195 from $210 and keeps a Neutral rating on the shares. The firm updated its ...

Bank of America Securities analyst Juan Avendano reiterated a Hold rating on Charles River Labs (CRL – Research Report) today and set a price ...

Chiefs-Bills national anthem has Chris Jones in tears as Super Bowl demand made As The H-1B Visa Debate Tears MAGA Apart, ...

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219 ...

Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...

The FDA has said it cannot approve tabelecleucel to treat patients 2 years of age and older who have EBV-positive PTLD and have received at least 1 prior therapy.